Exposure–Response Analyses for the MET Inhibitor Tepotinib Including Patients in the Pivotal VISION Trial: Support for Dosage RecommendationsCancer Chemother Pharmacol. 2022 Jul;90(1):53-69. Xiong W, Hietala SF, Nyberg J, Papasouliotis O, Johne A, Berghoff K, Goteti K, Dong J, Girard P, Venkatakrishnan K, Strotmann R.JournalMIDDOncologyPharmacometricsPharmetheus Affiliates Principal Director, Client Operations ManagerSofia Friberg HietalaSee bio Chief Technology OfficerJoakim NybergSee bio
